HIND vs RARE · rev $58.5K vs rev $350.0M
Vyome Holdings, Inc. (HIND) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Vyome Holdings, Inc. (HIND) is a biotechnology company listed on NASDAQ.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported HIND revenue for 2026-06-30 was $58.5K. Net income was -$1.6M. Revenue was up 85.3% from 2026-03-31 to 2026-06-30. HIND currently screens at market cap $16.1M.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
HIND currently screens at market cap $16.1M. RARE currently screens at market cap $2.79B.
Not investment advice. Open the HIND and RARE stock pages for the full models.
Not investment advice.